Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVO – Novo Nordisk A/S

Float Short %

0.79

Margin Of Safety %

29

Put/Call OI Ratio

0.82

EPS Next Q Diff

5.19

EPS Last/This Y

19.95

EPS This/Next Y

1.07

Price

49.46

Target Price

68.22

Analyst Recom

1.97

Performance Q

1.33

Relative Volume

1.25

Beta

0.65

Ticker: NVO




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-06NVO59.710.760.311292418
2025-10-07NVO59.110.760.611309594
2025-10-08NVO59.610.780.511329053
2025-10-09NVO58.70.770.591340031
2025-10-10NVO56.980.780.801353943
2025-10-13NVO57.50.790.801319815
2025-10-14NVO56.540.790.791337935
2025-10-15NVO56.730.790.821352866
2025-10-16NVO56.090.810.711368031
2025-10-17NVO54.350.800.741360269
2025-10-20NVO55.740.770.671195188
2025-10-21NVO54.80.770.531248404
2025-10-22NVO53.370.770.821274147
2025-10-23NVO53.230.770.701310141
2025-10-24NVO52.950.780.511326320
2025-10-27NVO52.90.790.771290705
2025-10-28NVO52.060.810.821334462
2025-10-29NVO51.40.811.321361982
2025-10-30NVO50.050.830.591405852
2025-10-31NVO49.40.820.551460467
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-06NVO59.67-28.3-269.723.94
2025-10-07NVO59.04-28.3-968.823.74
2025-10-08NVO59.62-28.3-134.023.74
2025-10-09NVO58.68-28.3-980.023.74
2025-10-10NVO56.93-28.3-1355.323.74
2025-10-13NVO57.50-28.3-995.323.74
2025-10-14NVO56.67-30.1-1305.623.74
2025-10-15NVO56.73-30.1-328.723.74
2025-10-16NVO56.07-29.7-778.923.56
2025-10-17NVO54.36-29.7-1556.223.56
2025-10-20NVO55.74-29.7420.423.56
2025-10-21NVO54.78-29.7-1034.423.56
2025-10-22NVO53.38-29.7-1294.223.48
2025-10-23NVO53.22-29.7-655.323.48
2025-10-24NVO52.98-29.7-724.523.48
2025-10-27NVO52.89-29.7-704.423.48
2025-10-28NVO52.05-29.7-1046.723.52
2025-10-29NVO51.39-29.7-1186.223.52
2025-10-30NVO50.04-29.7-1199.823.52
2025-10-31NVO49.46-29.7-706.223.52
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-06NVO0-1.450.85
2025-10-07NVO0-1.450.85
2025-10-08NVO0-1.450.85
2025-10-09NVO0-1.450.85
2025-10-10NVO0-1.450.93
2025-10-13NVO0-1.410.93
2025-10-14NVO0-1.410.93
2025-10-16NVO0-1.410.93
2025-10-17NVO0-1.410.93
2025-10-20NVO0-1.460.93
2025-10-21NVO0-1.460.93
2025-10-22NVO0-1.460.93
2025-10-23NVO0-1.460.93
2025-10-24NVO0-1.460.93
2025-10-27NVO0-1.500.79
2025-10-28NVO0-1.500.79
2025-10-29NVO0.00-1.500.79
2025-10-30NVO0.00-1.500.79
2025-10-31NVO0.00-1.500.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.97

Avg. EPS Est. Current Quarter

4.92

Avg. EPS Est. Next Quarter

6.16

Insider Transactions

Institutional Transactions

-1.5

Beta

0.65

Average Sales Estimate Current Quarter

76582

Average Sales Estimate Next Quarter

80738

Fair Value

63.98

Quality Score

99

Growth Score

98

Sentiment Score

26

Actual DrawDown %

66.6

Max Drawdown 5-Year %

-68.5

Target Price

68.22

P/E

13.63

Forward P/E

12.45

PEG

1.32

P/S

3.66

P/B

8.31

P/Free Cash Flow

17.55

EPS

3.63

Average EPS Est. Cur. Y​

23.52

EPS Next Y. (Est.)

24.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.6

Relative Volume

1.25

Return on Equity vs Sector %

41.5

Return on Equity vs Industry %

31.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.64

EBIT Estimation

-706.2
Novo Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 78387
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading